Kangmei Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to the parent of 36.03 million yuan, up 113.2% year on year. Operating revenue was 2.29 billion yuan, down 11.1% year on year. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 3.62 million yuan in the same period last year to a loss of 59.59 million yuan, with the loss widening further. Second-quarter net profit attributable to the parent was 52.6 million yuan, up 526.5% year on year. The company said that during the reporting period it actively advanced centralized procurement business, successfully winning bids for 41 product varieties, and that e-commerce channel sales performed well.
Kangmei Pharmaceutical Co LtdNet profit attributable to parent up 113.2% to 36.03 million yuan, though revenue fell and adjusted loss widened.
